CBIO Q4 2024 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$345M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$27,043

Operating Income

-$36M

Net Income

-$7M

EPS (Diluted)

$-0.11

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$11M

Total Liabilities

$6M

Stockholders' Equity

$5M

Cash & Equivalents

$11M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$10,000	-100.0%
Gross Profit	$27,043	$10,000	+170.4%
Operating Income	-$36M	-$10M	-276.0%
Net Income	-$7M	-$9M	+20.4%